Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2022-06-30

AUTHORS

Wenyuan Xiong, Sofia Friberg Hietala, Joakim Nyberg, Orestis Papasouliotis, Andreas Johne, Karin Berghoff, Kosalaram Goteti, Jennifer Dong, Pascal Girard, Karthik Venkatakrishnan, Rainer Strotmann

ABSTRACT

PurposeTepotinib is a highly selective MET inhibitor approved for treatment of non-small cell lung cancer (NSCLC) harboring METex14 skipping alterations. Analyses presented herein evaluated the relationship between tepotinib exposure, and efficacy and safety outcomes.MethodsExposure–efficacy analyses included data from an ongoing phase 2 study (VISION) investigating 500 mg/day tepotinib in NSCLC harboring METex14 skipping alterations. Efficacy endpoints included objective response, duration of response, and progression-free survival. Exposure–safety analyses included data from VISION, plus four completed studies in advanced solid tumors/hepatocellular carcinoma (30–1400 mg). Safety endpoints included edema, serum albumin, creatinine, amylase, lipase, alanine aminotransferase, aspartate aminotransferase, and QT interval corrected using Fridericia’s method (QTcF).ResultsTepotinib exhibited flat exposure–efficacy relationships for all endpoints within the exposure range observed with 500 mg/day. Tepotinib also exhibited flat exposure–safety relationships for all endpoints within the exposure range observed with 30–1400 mg doses. Edema is the most frequently reported adverse event and the most frequent cause of tepotinib dose reductions and interruptions; however, the effect plateaued at low exposures. Concentration-QTc analyses using data from 30 to 1400 mg tepotinib resulted in the upper bounds of the 90% confidence interval being less than 10 ms for the mean exposures at the therapeutic (500 mg) and supratherapeutic (1000 mg) doses.ConclusionsThese analyses provide important quantitative pharmacologic support for benefit/risk assessment of the 500 mg/day dosage of tepotinib as being appropriate for the treatment of NSCLC harboring METex14 skipping alterations.Registration NumbersNCT01014936, NCT01832506, NCT01988493, NCT02115373, NCT02864992. More... »

PAGES

53-69

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-022-04441-3

DOI

http://dx.doi.org/10.1007/s00280-022-04441-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1149107575

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35771259


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Non-Small-Cell Lung", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Edema", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mutation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Piperidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins c-met", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyridazines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrimidines", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Merck Institute of Pharmacometrics, Lausanne, Switzerland", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Merck Institute of Pharmacometrics, Lausanne, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xiong", 
        "givenName": "Wenyuan", 
        "id": "sg:person.016366654631.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016366654631.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pharmetheus AB, Uppsala, Sweden", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Pharmetheus AB, Uppsala, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hietala", 
        "givenName": "Sofia Friberg", 
        "id": "sg:person.01100743003.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100743003.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pharmetheus AB, Uppsala, Sweden", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Pharmetheus AB, Uppsala, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nyberg", 
        "givenName": "Joakim", 
        "id": "sg:person.0751421160.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751421160.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Merck Institute of Pharmacometrics, Lausanne, Switzerland", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Merck Institute of Pharmacometrics, Lausanne, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Papasouliotis", 
        "givenName": "Orestis", 
        "id": "sg:person.01163644113.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01163644113.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Merck Healthcare KGaA, Darmstadt, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Merck Healthcare KGaA, Darmstadt, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Johne", 
        "givenName": "Andreas", 
        "id": "sg:person.0720723135.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720723135.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Merck Healthcare KGaA, Darmstadt, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Merck Healthcare KGaA, Darmstadt, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Berghoff", 
        "givenName": "Karin", 
        "id": "sg:person.013424761570.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013424761570.94"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "EMD Serono Research and Development Institute Inc., Billerica, MA, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "EMD Serono Research and Development Institute Inc., Billerica, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Goteti", 
        "givenName": "Kosalaram", 
        "id": "sg:person.01311027771.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01311027771.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "EMD Serono Research and Development Institute Inc., Billerica, MA, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "EMD Serono Research and Development Institute Inc., Billerica, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dong", 
        "givenName": "Jennifer", 
        "id": "sg:person.015271642136.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015271642136.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Merck Institute of Pharmacometrics, Lausanne, Switzerland", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Merck Institute of Pharmacometrics, Lausanne, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Girard", 
        "givenName": "Pascal", 
        "id": "sg:person.012661201622.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012661201622.56"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "EMD Serono Research and Development Institute Inc., Billerica, MA, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "EMD Serono Research and Development Institute Inc., Billerica, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Venkatakrishnan", 
        "givenName": "Karthik", 
        "id": "sg:person.0774224760.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774224760.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Merck Healthcare KGaA, Darmstadt, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Merck Healthcare KGaA, Darmstadt, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Strotmann", 
        "givenName": "Rainer", 
        "id": "sg:person.011737527212.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011737527212.88"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1023/a:1011970125687", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042864451", 
          "https://doi.org/10.1023/a:1011970125687"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-020-00926-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1125955022", 
          "https://doi.org/10.1007/s10637-020-00926-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-3-319-91442-8_4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105951692", 
          "https://doi.org/10.1007/978-3-319-91442-8_4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41416-021-01334-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1136954523", 
          "https://doi.org/10.1038/s41416-021-01334-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10928-017-9558-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1095860080", 
          "https://doi.org/10.1007/s10928-017-9558-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41416-021-01380-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1137880805", 
          "https://doi.org/10.1038/s41416-021-01380-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-022-04423-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1146912411", 
          "https://doi.org/10.1007/s00280-022-04423-5"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-06-30", 
    "datePublishedReg": "2022-06-30", 
    "description": "PurposeTepotinib is a highly selective MET inhibitor approved for treatment of non-small cell lung cancer (NSCLC) harboring METex14 skipping alterations. Analyses presented herein evaluated the relationship between tepotinib exposure, and efficacy and safety outcomes.MethodsExposure\u2013efficacy analyses included data from an ongoing phase 2 study (VISION) investigating 500\u00a0mg/day tepotinib in NSCLC harboring METex14 skipping alterations. Efficacy endpoints included objective response, duration of response, and progression-free survival. Exposure\u2013safety analyses included data from VISION, plus four completed studies in advanced solid tumors/hepatocellular carcinoma (30\u20131400\u00a0mg). Safety endpoints included edema, serum albumin, creatinine, amylase, lipase, alanine aminotransferase, aspartate aminotransferase, and QT interval corrected using Fridericia\u2019s method (QTcF).ResultsTepotinib exhibited flat exposure\u2013efficacy relationships for all endpoints within the exposure range observed with 500\u00a0mg/day. Tepotinib also exhibited flat exposure\u2013safety relationships for all endpoints within the exposure range observed with 30\u20131400\u00a0mg doses. Edema is the most frequently reported adverse event and the most frequent cause of tepotinib dose reductions and interruptions; however, the effect plateaued at low exposures. Concentration-QTc analyses using data from 30 to 1400\u00a0mg tepotinib resulted in the upper bounds of the 90% confidence interval being less than 10\u00a0ms for the mean exposures at the therapeutic (500\u00a0mg) and supratherapeutic (1000\u00a0mg) doses.ConclusionsThese analyses provide important quantitative pharmacologic support for benefit/risk assessment of the 500\u00a0mg/day dosage of tepotinib as being appropriate for the treatment of NSCLC harboring METex14 skipping alterations.Registration NumbersNCT01014936, NCT01832506, NCT01988493, NCT02115373, NCT02864992.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00280-022-04441-3", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "90"
      }
    ], 
    "keywords": [
      "non-small cell lung cancer", 
      "MET inhibitors", 
      "treatment of NSCLC", 
      "ongoing phase 2 study", 
      "exposure-safety analyses", 
      "exposure-safety relationship", 
      "phase 2 study", 
      "progression-free survival", 
      "exposure-efficacy relationship", 
      "cell lung cancer", 
      "duration of response", 
      "exposure-response analysis", 
      "benefit/risk assessment", 
      "selective MET inhibitor", 
      "concentration-QTc analysis", 
      "exposure range", 
      "pharmacologic support", 
      "efficacy endpoint", 
      "safety endpoint", 
      "objective response", 
      "adverse events", 
      "VISION trial", 
      "day dosage", 
      "lung cancer", 
      "dosage recommendations", 
      "QT interval", 
      "hepatocellular carcinoma", 
      "alanine aminotransferase", 
      "frequent cause", 
      "safety outcomes", 
      "dose reduction", 
      "Fridericia's method", 
      "tepotinib", 
      "aspartate aminotransferase", 
      "mean exposure", 
      "endpoint", 
      "confidence intervals", 
      "ConclusionsThese analyses", 
      "low exposure", 
      "edema", 
      "aminotransferase", 
      "alterations", 
      "exposure", 
      "treatment", 
      "inhibitors", 
      "serum albumin", 
      "creatinine", 
      "patients", 
      "carcinoma", 
      "risk assessment", 
      "cancer", 
      "doses", 
      "trials", 
      "response", 
      "interval", 
      "efficacy", 
      "survival", 
      "outcomes", 
      "cause", 
      "study", 
      "duration", 
      "days", 
      "albumin", 
      "dosage", 
      "amylase", 
      "data", 
      "relationship", 
      "interruption", 
      "assessment", 
      "analysis", 
      "recommendations", 
      "support", 
      "ms", 
      "lipase", 
      "events", 
      "reduction", 
      "effect", 
      "vision", 
      "method", 
      "range", 
      "upper bounds", 
      "bounds"
    ], 
    "name": "Exposure\u2013response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations", 
    "pagination": "53-69", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1149107575"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-022-04441-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35771259"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-022-04441-3", 
      "https://app.dimensions.ai/details/publication/pub.1149107575"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:50", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_943.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00280-022-04441-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-022-04441-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-022-04441-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-022-04441-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-022-04441-3'


 

This table displays all metadata directly associated to this object as RDF triples.

287 TRIPLES      21 PREDICATES      124 URIs      109 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-022-04441-3 schema:about N0f161ae29efd4c9e9bedffffdc35b055
2 N143acd6b936048f28ac3e7d27c06a7f4
3 N2a7968eccf0c4173bec072cef2e26c77
4 N4e90ff7fb94b4db0b951d3de9d030c20
5 N5a17a1b105cf464abd0b8f7bc872ab75
6 N5b09f163682645d49250975c0a70fc6c
7 Nd62bbd575bb4470aa45b4061836e21ef
8 Necb1cb6a852843ad929fdfb27a46a883
9 Nf79e95e317894876a7c2d8ad36bf0119
10 Nfb0721f4b5134dd69a1667a52b23a84f
11 anzsrc-for:11
12 anzsrc-for:1117
13 schema:author N022f7eb1af6e4ae792b9695a046863d4
14 schema:citation sg:pub.10.1007/978-3-319-91442-8_4
15 sg:pub.10.1007/s00280-022-04423-5
16 sg:pub.10.1007/s10637-020-00926-1
17 sg:pub.10.1007/s10928-017-9558-5
18 sg:pub.10.1023/a:1011970125687
19 sg:pub.10.1038/s41416-021-01334-9
20 sg:pub.10.1038/s41416-021-01380-3
21 schema:datePublished 2022-06-30
22 schema:datePublishedReg 2022-06-30
23 schema:description PurposeTepotinib is a highly selective MET inhibitor approved for treatment of non-small cell lung cancer (NSCLC) harboring METex14 skipping alterations. Analyses presented herein evaluated the relationship between tepotinib exposure, and efficacy and safety outcomes.MethodsExposure–efficacy analyses included data from an ongoing phase 2 study (VISION) investigating 500 mg/day tepotinib in NSCLC harboring METex14 skipping alterations. Efficacy endpoints included objective response, duration of response, and progression-free survival. Exposure–safety analyses included data from VISION, plus four completed studies in advanced solid tumors/hepatocellular carcinoma (30–1400 mg). Safety endpoints included edema, serum albumin, creatinine, amylase, lipase, alanine aminotransferase, aspartate aminotransferase, and QT interval corrected using Fridericia’s method (QTcF).ResultsTepotinib exhibited flat exposure–efficacy relationships for all endpoints within the exposure range observed with 500 mg/day. Tepotinib also exhibited flat exposure–safety relationships for all endpoints within the exposure range observed with 30–1400 mg doses. Edema is the most frequently reported adverse event and the most frequent cause of tepotinib dose reductions and interruptions; however, the effect plateaued at low exposures. Concentration-QTc analyses using data from 30 to 1400 mg tepotinib resulted in the upper bounds of the 90% confidence interval being less than 10 ms for the mean exposures at the therapeutic (500 mg) and supratherapeutic (1000 mg) doses.ConclusionsThese analyses provide important quantitative pharmacologic support for benefit/risk assessment of the 500 mg/day dosage of tepotinib as being appropriate for the treatment of NSCLC harboring METex14 skipping alterations.Registration NumbersNCT01014936, NCT01832506, NCT01988493, NCT02115373, NCT02864992.
24 schema:genre article
25 schema:isAccessibleForFree true
26 schema:isPartOf N2b21a431773849c1af6f4bc119bd1f62
27 Na2b2ea6e302a43098a1867c0337fdfc0
28 sg:journal.1088364
29 schema:keywords ConclusionsThese analyses
30 Fridericia's method
31 MET inhibitors
32 QT interval
33 VISION trial
34 adverse events
35 alanine aminotransferase
36 albumin
37 alterations
38 aminotransferase
39 amylase
40 analysis
41 aspartate aminotransferase
42 assessment
43 benefit/risk assessment
44 bounds
45 cancer
46 carcinoma
47 cause
48 cell lung cancer
49 concentration-QTc analysis
50 confidence intervals
51 creatinine
52 data
53 day dosage
54 days
55 dosage
56 dosage recommendations
57 dose reduction
58 doses
59 duration
60 duration of response
61 edema
62 effect
63 efficacy
64 efficacy endpoint
65 endpoint
66 events
67 exposure
68 exposure range
69 exposure-efficacy relationship
70 exposure-response analysis
71 exposure-safety analyses
72 exposure-safety relationship
73 frequent cause
74 hepatocellular carcinoma
75 inhibitors
76 interruption
77 interval
78 lipase
79 low exposure
80 lung cancer
81 mean exposure
82 method
83 ms
84 non-small cell lung cancer
85 objective response
86 ongoing phase 2 study
87 outcomes
88 patients
89 pharmacologic support
90 phase 2 study
91 progression-free survival
92 range
93 recommendations
94 reduction
95 relationship
96 response
97 risk assessment
98 safety endpoint
99 safety outcomes
100 selective MET inhibitor
101 serum albumin
102 study
103 support
104 survival
105 tepotinib
106 treatment
107 treatment of NSCLC
108 trials
109 upper bounds
110 vision
111 schema:name Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations
112 schema:pagination 53-69
113 schema:productId N783e5017a2e543aca0839eddc47c5c59
114 Ncfd52d34df674302b85604c02c51900f
115 Nde8b9bdae1324f35a51f73cb7e5b9e0c
116 schema:sameAs https://app.dimensions.ai/details/publication/pub.1149107575
117 https://doi.org/10.1007/s00280-022-04441-3
118 schema:sdDatePublished 2022-10-01T06:50
119 schema:sdLicense https://scigraph.springernature.com/explorer/license/
120 schema:sdPublisher N8d8446505584477aa022045c916f5562
121 schema:url https://doi.org/10.1007/s00280-022-04441-3
122 sgo:license sg:explorer/license/
123 sgo:sdDataset articles
124 rdf:type schema:ScholarlyArticle
125 N022f7eb1af6e4ae792b9695a046863d4 rdf:first sg:person.016366654631.60
126 rdf:rest N253eb88dc6e1439299f9403900dbbe58
127 N0f161ae29efd4c9e9bedffffdc35b055 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Lung Neoplasms
129 rdf:type schema:DefinedTerm
130 N143acd6b936048f28ac3e7d27c06a7f4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Piperidines
132 rdf:type schema:DefinedTerm
133 N1bb4f04bb341485a959f9c45817ff38f rdf:first sg:person.013424761570.94
134 rdf:rest N4ea3fbf1d611480c8d13c3c9017752c6
135 N253eb88dc6e1439299f9403900dbbe58 rdf:first sg:person.01100743003.71
136 rdf:rest Nd2f7ffd2907449bd9b5e3735614dee71
137 N2a7968eccf0c4173bec072cef2e26c77 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Humans
139 rdf:type schema:DefinedTerm
140 N2b21a431773849c1af6f4bc119bd1f62 schema:issueNumber 1
141 rdf:type schema:PublicationIssue
142 N4e90ff7fb94b4db0b951d3de9d030c20 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Pyrimidines
144 rdf:type schema:DefinedTerm
145 N4ea3fbf1d611480c8d13c3c9017752c6 rdf:first sg:person.01311027771.58
146 rdf:rest Nb3c1ea48dce048c0866f0c6e1c384b61
147 N5a17a1b105cf464abd0b8f7bc872ab75 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Carcinoma, Non-Small-Cell Lung
149 rdf:type schema:DefinedTerm
150 N5b09f163682645d49250975c0a70fc6c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Proto-Oncogene Proteins c-met
152 rdf:type schema:DefinedTerm
153 N63638a99ffb749babf747ddae2d16331 rdf:first sg:person.012661201622.56
154 rdf:rest N722da499f6c445b6974059ffffb06908
155 N722da499f6c445b6974059ffffb06908 rdf:first sg:person.0774224760.21
156 rdf:rest Na8073975d32241b78021ef801076458a
157 N783e5017a2e543aca0839eddc47c5c59 schema:name doi
158 schema:value 10.1007/s00280-022-04441-3
159 rdf:type schema:PropertyValue
160 N8d8446505584477aa022045c916f5562 schema:name Springer Nature - SN SciGraph project
161 rdf:type schema:Organization
162 Na2b2ea6e302a43098a1867c0337fdfc0 schema:volumeNumber 90
163 rdf:type schema:PublicationVolume
164 Na8073975d32241b78021ef801076458a rdf:first sg:person.011737527212.88
165 rdf:rest rdf:nil
166 Nb3c162186bbc449aa6085b7acebe6ab5 rdf:first sg:person.01163644113.53
167 rdf:rest Ne83a68b330994726a7587bd1c274f3cb
168 Nb3c1ea48dce048c0866f0c6e1c384b61 rdf:first sg:person.015271642136.03
169 rdf:rest N63638a99ffb749babf747ddae2d16331
170 Ncfd52d34df674302b85604c02c51900f schema:name pubmed_id
171 schema:value 35771259
172 rdf:type schema:PropertyValue
173 Nd2f7ffd2907449bd9b5e3735614dee71 rdf:first sg:person.0751421160.21
174 rdf:rest Nb3c162186bbc449aa6085b7acebe6ab5
175 Nd62bbd575bb4470aa45b4061836e21ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Mutation
177 rdf:type schema:DefinedTerm
178 Nde8b9bdae1324f35a51f73cb7e5b9e0c schema:name dimensions_id
179 schema:value pub.1149107575
180 rdf:type schema:PropertyValue
181 Ne83a68b330994726a7587bd1c274f3cb rdf:first sg:person.0720723135.62
182 rdf:rest N1bb4f04bb341485a959f9c45817ff38f
183 Necb1cb6a852843ad929fdfb27a46a883 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Edema
185 rdf:type schema:DefinedTerm
186 Nf79e95e317894876a7c2d8ad36bf0119 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Pyridazines
188 rdf:type schema:DefinedTerm
189 Nfb0721f4b5134dd69a1667a52b23a84f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Protein Kinase Inhibitors
191 rdf:type schema:DefinedTerm
192 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
193 schema:name Medical and Health Sciences
194 rdf:type schema:DefinedTerm
195 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
196 schema:name Public Health and Health Services
197 rdf:type schema:DefinedTerm
198 sg:journal.1088364 schema:issn 0344-5704
199 1432-0843
200 schema:name Cancer Chemotherapy and Pharmacology
201 schema:publisher Springer Nature
202 rdf:type schema:Periodical
203 sg:person.01100743003.71 schema:affiliation grid-institutes:None
204 schema:familyName Hietala
205 schema:givenName Sofia Friberg
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100743003.71
207 rdf:type schema:Person
208 sg:person.01163644113.53 schema:affiliation grid-institutes:None
209 schema:familyName Papasouliotis
210 schema:givenName Orestis
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01163644113.53
212 rdf:type schema:Person
213 sg:person.011737527212.88 schema:affiliation grid-institutes:None
214 schema:familyName Strotmann
215 schema:givenName Rainer
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011737527212.88
217 rdf:type schema:Person
218 sg:person.012661201622.56 schema:affiliation grid-institutes:None
219 schema:familyName Girard
220 schema:givenName Pascal
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012661201622.56
222 rdf:type schema:Person
223 sg:person.01311027771.58 schema:affiliation grid-institutes:None
224 schema:familyName Goteti
225 schema:givenName Kosalaram
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01311027771.58
227 rdf:type schema:Person
228 sg:person.013424761570.94 schema:affiliation grid-institutes:None
229 schema:familyName Berghoff
230 schema:givenName Karin
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013424761570.94
232 rdf:type schema:Person
233 sg:person.015271642136.03 schema:affiliation grid-institutes:None
234 schema:familyName Dong
235 schema:givenName Jennifer
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015271642136.03
237 rdf:type schema:Person
238 sg:person.016366654631.60 schema:affiliation grid-institutes:None
239 schema:familyName Xiong
240 schema:givenName Wenyuan
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016366654631.60
242 rdf:type schema:Person
243 sg:person.0720723135.62 schema:affiliation grid-institutes:None
244 schema:familyName Johne
245 schema:givenName Andreas
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720723135.62
247 rdf:type schema:Person
248 sg:person.0751421160.21 schema:affiliation grid-institutes:None
249 schema:familyName Nyberg
250 schema:givenName Joakim
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751421160.21
252 rdf:type schema:Person
253 sg:person.0774224760.21 schema:affiliation grid-institutes:None
254 schema:familyName Venkatakrishnan
255 schema:givenName Karthik
256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774224760.21
257 rdf:type schema:Person
258 sg:pub.10.1007/978-3-319-91442-8_4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105951692
259 https://doi.org/10.1007/978-3-319-91442-8_4
260 rdf:type schema:CreativeWork
261 sg:pub.10.1007/s00280-022-04423-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1146912411
262 https://doi.org/10.1007/s00280-022-04423-5
263 rdf:type schema:CreativeWork
264 sg:pub.10.1007/s10637-020-00926-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1125955022
265 https://doi.org/10.1007/s10637-020-00926-1
266 rdf:type schema:CreativeWork
267 sg:pub.10.1007/s10928-017-9558-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1095860080
268 https://doi.org/10.1007/s10928-017-9558-5
269 rdf:type schema:CreativeWork
270 sg:pub.10.1023/a:1011970125687 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042864451
271 https://doi.org/10.1023/a:1011970125687
272 rdf:type schema:CreativeWork
273 sg:pub.10.1038/s41416-021-01334-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1136954523
274 https://doi.org/10.1038/s41416-021-01334-9
275 rdf:type schema:CreativeWork
276 sg:pub.10.1038/s41416-021-01380-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1137880805
277 https://doi.org/10.1038/s41416-021-01380-3
278 rdf:type schema:CreativeWork
279 grid-institutes:None schema:alternateName EMD Serono Research and Development Institute Inc., Billerica, MA, USA
280 Merck Healthcare KGaA, Darmstadt, Germany
281 Merck Institute of Pharmacometrics, Lausanne, Switzerland
282 Pharmetheus AB, Uppsala, Sweden
283 schema:name EMD Serono Research and Development Institute Inc., Billerica, MA, USA
284 Merck Healthcare KGaA, Darmstadt, Germany
285 Merck Institute of Pharmacometrics, Lausanne, Switzerland
286 Pharmetheus AB, Uppsala, Sweden
287 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...